Cost-Effectiveness of Lecanemab for Individuals With Early-Stage Alzheimer Disease | Neurology
Background and ObjectivesLittle is known regarding the cost-effectiveness of lecanemab (Leqembi), a monoclonal antibody approved by the US Food and Drug Administration in January 2023 for the treatment of mild cognitive impairment (MCI) or mild dementia …